Table 1 Clinical and aortic wall characteristics of the study population
Characteristics | Acute coronary syndrome n = 27 | Non-cardiac chest pain (ED) n = 51 | Asymptomatic diabetes (Control group) n = 45 | p-value |
|---|---|---|---|---|
Age (yrs) | 60.3 ± 11.4 | 53.6 ± 10.7 | 59.9 ± 8 | |
Gender (female) | 52.2% | 47% | 44.5% | |
BMI | 29.19 | 19.85 | 14.10 | |
Past medical history: | ||||
Smoker | 43.5% | 13.7% | 11.1% | |
Hypertension | 78.2% | 49% | 75.5% | |
Diabetes Type 2 | 21.7% | 17.7% | 100% | |
Hyperlipidemia | 30.4% | 37.3% | 73.3% | |
Family history of: | ||||
CAD | 34.8% | 39.2% | 33.3% | |
Angina | 91.3% | 53% | 0 | |
MI | 4.3% | 0 | 0 | |
Coronary angiography | 4.3% | 5.9% | 0 | |
Claudication | 34.8% | 0 | 6.7% | |
Renal disease | 8.7% | 3.9% | 0 | |
CVA/TIA | 13% | 7.8% | 6.7% | |
Blood tests: | ||||
Troponin | 1.37 ± 2.1 | NA | NA | |
CKMB | 61.9 ± 71.1 | NA | NA | |
Creatinine | 1.1 ± 0.33 | 1.1 ± 0.9 | 1.09 ± 0.8 | |
LDL | 109 ± 46.2 | 104 ± 36.6 | 107.8 ± 36.3 | |
HDL | 47 ± 11.8 | 47.5 ± 16.2 | 50.04 ± 11.8 | |
Triglycerides | 149.8 ± 101.7 | 149.7 ± 76.2 | 212.5 ± 143 | |
Total cholesterol | 181.8 ± 51.3 | 183.9 ± 43 | 198.25 ± 41 | |
CRP | 2.16 ± 1.8 | 0.51 ± 0.6 | 0.61 ± 0.9 | |
Medications: | ||||
Aspirin | 21.8% | 33.3% | 62.2% | |
Plavix | 0 | 0 | 0 | |
Beta blockers | 4.3% | 17.6% | 20% | |
ACEI | 34.8% | 23.5% | 55.5% | |
ARB | 0 | 0 | 17.8% | |
Statin | 43.4% | 27.5% | 53.5% | |
Diuretics | 26.1% | 13.7% | - | |
Aortic wall characteristics: | ||||
Wall thickness (mm) | ||||
Mean | 3.173 ± 0.2 | 2.576 ± 0.1 | 2.305 ± 0.13 | |
Min-Max | 2.0–5.4 | 1.1–4.0 | 1.2–4.2 | <0.001 |
Wall area (mm2) | ||||
Mean | 2.114 ± 0.2 | 1.526 ± 0.06 | 1.382 ± 0.06 | |
Min-Max | 1.17–4.3 | 0.77–2.7 | 0.70–1.99 | <0.001 |
Lumen area (mm2) | ||||
Mean | 4.501 ± 0.248 | 4.3076 ± 0.136 | 4.006 ± 0.136 | |
Min-Max | 2.36–8.22 | 2.69–8.2 | 1.58–7.22 | 0.136 |